Research Suggests Parkinson’s Disease May Not Begin in the Brain

New Study Links Kidneys to Parkinson’s Disease Onset

Parkinson’s disease is often linked to neurological damage in the brain, primarily caused by a significant drop in dopamine levels. However, recent research suggests that the disease may actually begin in an unexpected location: the kidneys.

A team from Wuhan University in China led the study, focusing on the alpha-synuclein (α-Syn) protein, which is known for its connection to Parkinson’s. When produced incorrectly, this protein can form clumps that disrupt brain function.

The key finding indicates that these α-Syn clumps can accumulate in the kidneys, not just the brain. Researchers propose that these misfolded proteins could travel from the kidneys to the brain, potentially triggering the onset of the disease.

“We demonstrate that the kidney is a peripheral organ that serves as an origin of pathological α-Syn,” the researchers noted in their published paper.

The study involved a variety of tests, including analyzing the behavior of α-Syn in genetically modified mice and examining human tissue. This included samples from individuals with Parkinson’s and chronic kidney disease.

Interestingly, abnormal α-Syn growth was found in the kidneys of 10 out of 11 individuals with Parkinson’s and other dementia-related disorders. Further tests also revealed similar protein issues in 17 out of 20 patients with chronic kidney disease, even when they showed no neurological symptoms. This suggests that the kidneys might be where these harmful proteins begin to accumulate before causing brain damage.

Animal tests supported these theories. Mice with healthy kidneys effectively cleared injected α-Syn clumps, whereas those with dysfunctional kidneys experienced buildups that eventually spread to the brain. When the nerves connecting the kidneys and brain were severed, this spreading didn’t occur.

Since α-Syn proteins can also circulate through the bloodstream, the researchers investigated this aspect as well. They discovered that a decrease in α-Syn in the blood correlates with reduced brain damage, adding another layer to consider.

Despite its intriguing findings, the study has limitations. The number of participants from whom tissue samples were taken was relatively small, and while mice can provide useful insights, it’s uncertain whether the same processes occur in humans.

Nonetheless, this research opens up various avenues for further exploration that could lead to advancements in treating Parkinson’s and related neurological disorders.

It’s likely that Parkinson’s, similar to Alzheimer’s, is triggered by a combination of factors and risk elements. Previous studies have suggested that it could even start in the gut, and this new research hints at a possible connection with the kidneys as well.

“Removal of α-Syn from the blood may hinder the progression of Parkinson’s disease, providing new strategies for therapeutic management of Lewy body diseases,” the researchers concluded.